Anti-PD-L1 / anti-PD-1 natural antibody structure-mimicking heterodimer bispecific antibody and method for preparing same
A stable heterodimeric bispecific antibody with tailored Fc chains effectively binds PD-L1 and PD-1, addressing production and immunogenicity issues, and enhances tumor treatment by recruiting immune cells with reduced toxicity.
Patent Information
- Application Number
- JP2020502753
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-04-01
- Filing Date
- 2018-03-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2038-03-28
AI Technical Summary
Existing bispecific antibodies targeting PD-1/PD-L1 and CD80/PD-L1 have limitations such as low production yield, complexity in purification, short serum half-life, and high immunogenicity, as well as significant side effects like cytokine storms, necessitating the development of more stable and effective bifunctional antibodies.
A highly stable heterodimeric bispecific antibody with natural IgG-like structure, featuring specific amino acid substitutions in the Fc chains to promote heterodimer formation and inhibit homodimer formation, allowing simultaneous binding to PD-L1 and PD-1, and potentially CD80/PD-L1, with reduced mismatched heavy-light chains.
The antibody achieves enhanced tumor treatment efficacy by recruiting immune cells to tumor surfaces with reduced toxicity, demonstrating stronger antitumor effects than monoclonal antibodies and combinations, and maintaining high affinity for PD-L1 and PD-1 targets.
Smart Images

Figure 0007579703000002 
Figure 0007579703000003 
Figure 0007579703000004
Abstract
Description
[Technical field]
[0001] The present invention relates to an anti-PD-L1 / anti-PD-1 native antibody structure-like heterodimeric bispecific antibody and a method for preparing the same. Specifically, the present invention provides a highly stable heterodimeric anti-PD-L1 / anti-PD-1 bispecific antibody that has the characteristics of native IgG and has no mismatched heavy chain-light chains, and a method for preparing the same. [Background technology]
[0002] Monoclonal antibodies are highly specific antibodies that only act against a single antigenic epitope, and are widely used in the treatment of many diseases, such as cancer, inflammation and autoimmune diseases, and infectious diseases. However, due to the complexity of diseases, none of these therapeutic molecules show sufficient efficacy when used alone. For example, cancer or inflammatory diseases are often associated with the interaction of various disease-mediated molecular pathways and signal transduction pathways. Under such circumstances, a single targeting molecule may not provide optimal therapeutic effects, while the therapeutic effect may be improved by a molecule that simultaneously blocks multiple targets or multiple sites of a single target. On the other hand, dual targeting therapy using multispecific, e.g. bispecific molecules, may simplify the development of new drugs, because such molecules are single molecules. Compared with the combined administration of multiple monospecific molecules, it will be more convenient for both patients and caregivers.
[0003] Many different formats of bispecific antibodies or bifunctional molecules have been reported in the art. The first bispecific antibodies were obtained by chemical methods using bifunctional coupling reagents to link together two existing IgG molecules, Fab', or (Fab')2 fragments. However, such chemically coupled bispecific antibodies have many limitations, such as the labor intensity of production, the purification of heterologous conjugates, the complexity of removing homologous conjugates and the original monospecific antibodies or fragments, and low yields.
[0004] Another method for producing bispecific antibodies utilizes the technology of hybrid-hybridomas (or quadromas), which are produced by somatic cell fusion of two hybridoma cell lines secreting different antibodies. Due to the random pairing of immunoglobulin heavy and light chains, the desired functional bispecific antibody is only 1 / 10 of the antibody mixture, which complicates the purification process and reduces the production yield.
[0005] Patent document 1: WO 2013 / 060867 describes a method for the mass production of heterodimeric bispecific antibodies, in which two homodimeric antibodies are first reduced in a mixture, then asymmetric amino acid mutations are introduced into the CH3 regions of the two homodimeric antibodies to promote Fab arm exchange between the different antibodies, and a stable bispecific antibody is finally formed by oxidation of the interchain disulfide bonds in the hinge region.
[0006] Patent document 2: WO 2009 / 089004 describes a method for preparing heterodimeric proteins, in which amino acids at the CH3-CH3 interface are mutated to charged amino acids such that the formation of heterodimers is electrostatically favored while the formation of homodimers is electrostatically disfavored.
[0007] Patent document 3: US Patent No. 5731168 describes a method for preparing heterodimeric IgG according to a "protuberance-into-cavity" strategy, where "protuberances" are constructed by replacing small amino acids at the interface of the CH3 region of the first chain with larger amino acids, and at the same time "cavities" are created by replacing the corresponding large amino acids at the CH3 interface of the second chain with smaller amino acids. The interaction between the protuberances and the cavities favors the formation of heterodimeric IgG, but not the formation of homodimers.
[0008] Patent document 4: WO 2012 / 058768 describes a method for preparing stable and highly specific heterodimeric IgG, which combines both negative and positive design along with computer structural modeling guided protein engineering techniques to mutate multiple amino acids in the CH3 domain of IgG1, thereby forming a stable heterodimeric IgG with a low content of homodimeric impurities.
[0009] As an effective means to improve the efficacy of antibodies, bifunctional antibodies capable of recruiting effector cells can be designed. To date, the utilization of the function of the CD3 molecule has been the most studied. By activating killer T cells with CD3 molecules, tumors of interest can be effectively eliminated (Haas C. et al., Immunobiology, 214:441-453, 2009). Among the above, BiTE, a recombinant bifunctional T cell stimulating antibody developed by Micromet, Inc., has shown considerable promise. However, the biggest challenge is its very short serum half-life, with its half-life in the human body being only 1 hour (Loffler A. et al., Blood, 95:2098-2103). This is due to the structure of BiTE itself, which is composed of two single-chain antibody fragments with a molecular weight of only 60 kDa and lacks the Fc fragment in the antibody molecule, which has a significant effect on half-life extension.
[0010] Another promising multifunctional antibody, catumaxomab, is a hybrid Ig molecule that targets CD3 and EpCAM. Recently, this product has been approved for the treatment of ascites carcinoma (Jager M. et al., Cancer Res, 72:24-32, 2012). Yet another multifunctional antibody under phase II clinical trials is ertumaxomab, which targets CD3 and PD-L1. One heavy chain and one light chain of the hybrid antibody are derived from rat IgG and target CD3, and the other heavy and light chains are derived from mouse IgG and target PD-L1. As a result, there is a problem that the production of such a product is very difficult, since a quadroma capable of expressing a bifunctional anti-CD3 / anti-PD-L1 antibody requires obtaining a cell line expressing the bifunctional ertumaxomab. Said quadroma is obtained by first obtaining a diploid hybridoma line expressing CD3 antibody and a diploid hybridoma line expressing PD-L1 antibody, and then hybridizing the two hybridoma lines. In contrast, only one diploid hybridoma line is required for the production of traditional single-targeting antibodies. In comparison, the production process of bifunctional antibodies is more complicated, since it is much more difficult to obtain quadromas. In addition, the mouse origin leads to its very high immunogenicity.
[0011] Moreover, the most obvious side effect caused by anti-CD3 antibodies is a short-term burst of cytokines in vivo, also called cytokine storm. Therefore, novel bifunctional antibodies that simultaneously recruit tumor cells to the surface of tumor cells are needed.
[0012] Programmed death receptor-1 (PD-1) is an immune checkpoint that has attracted much attention in recent years. PD-1 is a member of the CD28 family. Unlike other members of the CD28 family, such as CTLA4, which can form covalent dimers via disulfide bonds, PD-1 exists in a monomeric form. The structure of PD-1 mainly includes an immunoglobulin variable region-like extracellular domain, a hydrophobic transmembrane domain, and an intracellular domain. The intracellular domain contains two independent phosphorylation sites: immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs), respectively. PD-1 is mainly expressed on the surface of activated T cells, and also inducibly on B cells, NK cells, monocytes, and DC cells. PD-1 is mainly involved in the negative control of T cell activation and can regulate the intensity and duration of immune responses. Ligands of PD-1 include PD-L1 (programmed death ligand 1) and PD-L2 (programmed death ligand 2). These ligands belong to the B7 family. In the above, PD-L1 is inducibly expressed on the surface of various immune cells, including T cells, B cells, monocytes, macrophages, DC cells, endothelial cells, epithelial cells, etc., whereas PD-L2 is inducibly expressed only on some immune cells, including macrophages, DC cells, and B cells. PD-L1 not only acts as a ligand for PD-1, but also as a ligand for CD80, transmitting negative regulatory signals to T cells and inducing immune tolerance in T cells (Non-Patent Document 4: Autoimmun Rev, 2013, 12(11):1091-1100; Non-Patent Document 5: Front Immuno1, 2013, 4:481; Non-Patent Document 6: Nat Rev Cancer, 2012, 12(4):252-264; Non-Patent Document 7: Trends Mo1 Med. 2015 Jan;21(1):24-33; Non-Patent Document 8: Clin Cancer Res. 2012 Dec 15;18(24):6580-7).
[0013] Under normal circumstances, PD-1 and PD-L1 can mediate and maintain the self-immune tolerance of vital tissues, prevent the immune system from overactivating and damaging self-tissues in the inflammatory process, and have a positive effect on avoiding the occurrence of autoimmune diseases. Under pathological circumstances, they are involved in tumor immunity and the occurrence and development of various autoimmune diseases. There are several publications reporting that PD-L1 is highly expressed in various tumor tissues and PD-1 is highly expressed in tumor-infiltrating lymphocytes. Furthermore, overexpression of PD-L1 and PD-1 is closely associated with poor clinical prognosis of tumors (Non-Patent Document 9: Anticancer Agents Med Chem. 2015; 15(3): 307-13, Non-Patent Document 10: Hemato1 Onco1 Stem Cell Ther. 2014 Mar; 7(1): 1-17, Non-Patent Document 11: Trends Met Med. 2015 Jan; 21(1): 24-33, Non-Patent Document 12: Immunity. 2013 Jul 25; 39(1): 61-73, Non-Patent Document 13: J Clin Onco1. 2015 Jun 10; 33(17): 1974-82). Blocking PD-1 / PD-L1 and PD-1 / PD-L2 with PD-1 mAb, or blocking PD-1 / PD-L1 and CD80 / PD-L1 with PD-L1 mAb, has shown satisfactory antitumor effects in both preclinical and clinical trials. At present, PD-1 mAb has been approved by the US Food and Drug Administration for the treatment of various tumors, including non-small cell lung cancer, melanoma, head and neck cancer, etc. PD-L1 mAb has also been approved for the treatment of non-small cell lung cancer and urothelial carcinoma. However, although a small proportion of tumor patients can benefit from such monoclonal antibody therapy, most patients do not respond to such monoclonal antibodies (Non-Patent Document 14: Expert Opin Ther Targets. 2014 Dec; 18(12): 1407-20, Non-Patent Document 15: Oncology (Wi11ston Park). 2014 Nov; 28 Suppl3: 15-28). [Prior art documents] [Chartered documents]
[0014]
Patent Document 1
Patent document 2
Patent Document 3
Patent document 4
Non-licensed literature
[0015]
Non-licensed literature 1
Non-licensed Document 2
Non-licensed Document 4
Non-licensed Document 5
Non-licensed Document 6
Non-licensed Document 7
Non-licensed Document 8
Non-licensed literature 9
Non-licensed literature 10
[0016] Therefore, it is necessary to develop novel and more effective bifunctional antibodies that simultaneously block PD-1 / PD-L1, PD-1 / PD-L2 and CD80 / PD-L1 and recruit immune cells to the surface of tumor cells. [Means for solving the problem]
[0017] Summary of the Invention The present invention provides a highly stable heterodimeric bispecific antibody that has the structural characteristics of natural IgG, does not have mismatched heavy chain-light chains, and can simultaneously block PD-L1 and PD-1, and provides a method for preparing the same. The bifunctional antibody simultaneously binds to PD-L1 expressed on tumor cells and PD-1 expressed on immune cells, thereby simultaneously exerting highly effective and specific killing effects and low toxic side effects.
[0018] In a first aspect, the present invention relates to a heterodimeric bispecific antibody comprising a first antigen-binding functional region capable of specifically binding to PD-L1 and a second antigen-binding functional region capable of specifically binding to PD-1, wherein the bispecific antibody comprises a first Fc chain and a second Fc chain linked by one or more interchain disulfide bonds, wherein the first Fc chain and the second Fc chain are linked to the PD-L1 antigen-binding functional region and the PD-1 antigen-binding functional region by a covalent bond or a linker, respectively, and the first Fc chain and the second Fc chain comprise five amino acid substitutions at the following positions: amino acid substitutions at positions 366 and 399 on the first Fc chain and amino acid substitutions at positions 351, 407 and 409 on the second Fc chain, wherein the first Fc chain and the second Fc chain comprising the above mentioned amino acid substitutions tend to form heterodimers with each other rather than forming homodimers with each other, and the amino acid positions are numbered according to the Kabat EU index numbering system.
[0019] In some embodiments, the amino acid substitutions in the first Fc chain and the second Fc chain are as follows: a) substitution at position 351 with glycine, tyrosine, valine, proline, aspartic acid, glutamic acid, lysine or tryptophan; b) substitution at position 366 with leucine, proline, tryptophan or valine; c) a substitution at position 399 with cysteine, asparagine, isoleucine, glycine, arginine, threonine or alanine; d) a substitution at position 407 with leucine, alanine, proline, phenylalanine, threonine or histidine; e) Substitution at position 409 with cysteine, proline, serine, phenylalanine, valine, glutamine or arginine.
[0020] In some embodiments, the amino acid substitutions are as follows: a) T366L and D399R substitutions on the first Fc chain, L351E, Y407L and K409V substitutions on the second Fc chain; b) T366L and D399C substitutions on the first Fc chain, L351G, Y407L and K409C substitutions on the second Fc chain; c) T366L and D399C substitutions on the first Fc chain, L351Y, Y407A and K409P substitutions on the second Fc chain; d) T366P and D399N substitutions on the first Fc chain, L351V, Y407P and K409S substitutions on the second Fc chain; e) T366W and D399G substitutions on the first Fc chain, L351D, Y407P and K409S substitutions on the second Fc chain; f) T366P and D399I substitutions on the first Fc chain, L351P, Y407F and K409F substitutions on the second Fc chain; g) T366V and D399T substitutions on the first Fc chain, L351K, Y407T and K409Q substitutions on the second Fc chain; h) T366L and D399A substitutions on the first Fc chain, L351W, Y407H and K409R substitutions on the second Fc chain.
[0021] In some embodiments, the amino acid substitutions on the first Fc chain are T366L and D399R and the amino acid substitutions on the second Fc chain are L351E, Y407L and K409V.
[0022] In some embodiments, the Fc chain is derived from an IgG.
[0023] In some embodiments, the PD-L1 antigen-binding functional region and the PD-1 antigen-binding functional region are Fab fragments or scFv fragments.
[0024] In some embodiments, the PD-L1 antigen binding functional region and the PD-1 antigen binding functional region are both Fab fragments.
[0025] In some embodiments, one of the PD-L1 antigen-binding functional region and the PD-1 antigen-binding functional region is a Fab fragment, and the other is an scFv.
[0026] In some embodiments, the Fab fragment comprises a first heavy chain variable region and a second heavy chain variable region that differ, and a first light chain variable region and a second light chain variable region that differ.
[0027] In some embodiments, the amino acid sequence of the bispecific antibody is selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, and 18.
[0028] In a second aspect, the present invention relates to an isolated polynucleotide encoding the heterodimeric bispecific antibody according to the first aspect.
[0029] In some embodiments, the sequence of the polynucleotide is selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, and 17.
[0030] In a third aspect, the present invention relates to a recombinant expression vector comprising the isolated polynucleotide according to the second aspect.
[0031] In some embodiments, the expression vector is the plasmid vector X0GC obtained by pCDNA-based engineering.
[0032] In a fourth aspect, the present invention relates to a host cell comprising an isolated polynucleotide according to the second aspect, or a recombinant expression vector according to the third aspect.
[0033] In some embodiments, the host cell is a human embryonic kidney cell HEK293 or a cell obtained by engineering based on HEK293 cells, such as HEK293T, HEK293F, HEK293E, a hamster ovary cell CHO or CHO-S, CHO-dhfr -, CHO / DG44, ExpiCHO-based engineered cells, Escherichia coli or strains thereof such as BL21, BL21(DE3), Rosetta, Origami, yeast or strains thereof such as Pichia pastoris, Saccharomyces cerevisiae, Kluyveromyces cerevisiae, Hansenula polymorpha, insect cells or cells thereof such as High5, SF9, plant cells, mammalian breast cells, somatic cells, etc.
[0034] In a fifth aspect, the present invention relates to a composition comprising a heterodimeric bispecific antibody according to the first aspect, or an isolated polynucleotide according to the second aspect, or a recombinant expression vector according to the third aspect, or a host cell according to the fourth aspect, and a pharma- ceutically acceptable carrier.
[0035] In a sixth aspect, the present invention provides a method for producing a heterodimeric bispecific antibody according to the first aspect, comprising: 1) separately expressing in a host cell an isolated polynucleotide according to the second aspect or a recombinant expression vector according to the third aspect; 2) reducing the separately expressed proteins in the host cell; 3) mixing the reduced protein and then oxidizing the mixture.
[0036] In some embodiments, the host cell is a human embryonic kidney cell HEK293 or a cell obtained by engineering based on HEK293 cells, such as HEK293T, HEK293F, HEK293E, a hamster ovary cell CHO or CHO-S, CHO-dhfr -, CHO / DG44, ExpiCHO-based engineered cells, Escherichia coli or strains thereof such as BL21, BL21(DE3), Rosetta, Origami, yeast or strains thereof such as Pichia pastoris, Saccharomyces cerevisiae, Kluyveromyces cerevisiae, Hansenula polymorpha, insect cells or cells thereof such as High5, SF9, plant cells, mammalian breast cells, somatic cells, etc.
[0037] In some embodiments, the reducing step comprises 1) performing a reduction reaction, wherein a reducing agent is selected from the group consisting of 2-mercaptoethylamine, dithiothreitol, tris(2-carboxyethyl)phosphine or chemical derivatives thereof, or combinations thereof, and 2) removing the reducing agent.
[0038] In some embodiments, the oxidizing step is an oxidation in air, but also includes carrying out the oxidation reaction in the presence of an oxidizing agent selected from the group consisting of L-dehydroascorbic acid or other chemical derivatives.
[0039] In some embodiments, the method further comprises a separation and purification step.
[0040] In a seventh aspect, the present invention relates to the use of a heterodimeric bispecific antibody according to the first aspect, and / or an isolated polynucleotide according to the second aspect, and / or a recombinant expression vector according to the third aspect, and / or a host cell according to the fourth aspect, and / or a composition according to the fifth aspect, in the manufacture of a medicament for preventing and / or treating a disease in a subject.
[0041] In an eighth aspect, the present invention relates to a heterodimeric bispecific antibody according to the first aspect, and / or an isolated polynucleotide according to the second aspect, and / or a recombinant expression vector according to the third aspect, and / or a host cell according to the fourth aspect, and / or a composition according to the fifth aspect, for use as a medicament for preventing and / or treating a disease in a subject.
[0042] In a ninth aspect, the present invention relates to a method for preventing and / or treating a disease comprising administering to a subject in need thereof a heterodimeric bispecific antibody according to the first aspect, and / or an isolated polynucleotide according to the second aspect, and / or a recombinant expression vector according to the third aspect, and / or a host cell according to the fourth aspect, and / or a composition according to the fifth aspect.
[0043] In some embodiments, the subject is a mammal, preferably a human subject.
[0044] In some embodiments, the disease is a tumor selected from the group consisting of leukemia, lymphoma, myeloma, brain cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, nasopharyngeal cancer, esophageal cancer, gastric cancer, pancreatic cancer, gallbladder cancer, liver cancer, colorectal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, bladder cancer, renal cell carcinoma, and melanoma.
[0045] The present inventors design a completely new anti-PD-L1 / anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody, which is a highly stable heterodimeric anti-PD-L1 / anti-PD-1 bispecific antibody with the characteristics of natural IgG and no mismatched heavy-light chains, which can simultaneously bind to two target molecules, PD-L1 and PD-1, simultaneously block PD-1 / PD-L1, PD-1 / PD-L2 and CD80 / PD-L1, and recruit immune cells to the surface of tumor cells, and should show stronger efficacy in tumor treatment. [Brief description of the drawings]
[0046] [Figure 1] FIG. 1 shows the elution peak of the monomer of a heterodimeric antibody molecule. [Diagram 2] FIG. 2 shows an SDS-PAGE analysis of monomers of the heterodimeric antibody molecule. [Diagram 3] Figure 3 shows the structure of the anti-PD-L1 / anti-PD-1 heterodimeric antibody molecule. [Figure 4] FIG. 4 shows the schematic structure of a half antibody molecule of one heavy and one light chain. [Diagram 5] Figure 5 shows the results of SDS-PAGE analysis of the oxidation products of half antibody molecules of anti-PD-L1 and anti-PD-1 antibodies. [Figure 6] Figure 6 shows the elution peaks of anti-PD-L1 / anti-PD-1 heterodimer antibody molecules. [Figure 7] Figure 7 shows the results of SDS-PAGE analysis of anti-PD-L1 / anti-PD-1 heterodimer antibody molecules. [Figure 8] Figure 8 shows the results of SEC analysis of anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules. [Figure 9] Figure 9 shows the PD-L1 binding activity and PD-1 binding activity of anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules, Panel A and Panel B show the PD-L1 binding activity and PD-1 binding activity, respectively. [Figure 10] Figure 10 shows that the anti-PD-L1 / anti-PD-1 heterodimeric antibody molecule simultaneously binds to SK-BR-3 cells with high expression of PD-L1 and to CHO / PD-1 cells with high expression of PD-1, Panels A-D show the binding to PD-L1 mAb, PD-1 mAb, PD-L1 mAb+PD-1 mAb, and anti-PD-L1 / anti-PD-1BJHM, respectively. [Figure 11] Figure 11 shows that anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules promote the secretion of cytokines IL-2 and IFN-γ. [Figure 12]Figure 12 shows the in vitro killing activity of PD-L1 / PD-1 heterodimeric antibody molecules against tumor cells. [Figure 13] Figure 13 shows the killing activity of anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules against tumor cells in a mouse model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0047] Detailed Description of the Invention definition In heterodimeric bispecific antibodies, "covalent bond" refers to a covalent bond between two Fc chains or between any one of the Fc chains and each antigen-binding functional region to form a molecule, wherein the Fc chain comprises a first antigen-binding functional region and a second antigen-binding functional region linked by one or more covalent bonds (e.g., disulfide bonds), and the first Fc chain and the second Fc chain are each linked to the antigen-binding functional region via a covalent bond (such as an imine bond or an amide bond).
[0048] The antigen-binding functional region refers to a region that can specifically interact with a target molecule such as an antigen. Such interaction is highly selective. Generally, a sequence that recognizes one target molecule cannot recognize a sequence of another molecule. Representative antigen-binding functional regions include antibody variable regions, allosteric antibody variable regions, receptor binding regions, ligand binding regions, or enzyme binding regions.
[0049] One or more "interchain disulfide bonds" refers to one or more disulfide bonds between the first Fc chain and the second Fc chain, which bind the chains to form a heterodimeric fragment. In the present invention, one or more disulfide bonds can be formed when the first Fc chain and the second Fc chain, or the first Fc chain and the second Fc chain and the antigen-binding functional region linked thereto, are synthesized in the same cell, or the first Fc chain and the second Fc chain, or the first Fc chain and the second Fc chain and the antigen-binding functional region linked thereto are synthesized separately in different cells and then formed by an in vitro reduction-oxidation process.
[0050] The first Fc chain and the second Fc chain refer to a combined fragment formed by a covalent bond, the covalent bond comprising a disulfide bond.
[0051] Each chain comprises at least a portion of an immunoglobulin heavy chain constant region. Moreover, the first chain and the second chain differ in amino acid sequence, such as a difference at at least one amino acid position. In the first Fc chain and the second Fc chain of the present invention, there is a strong repulsive force between the same chain, while there is an attractive force between different chains. Thus, the first Fc chain and the second Fc chain, or the first Fc chain and the second Fc chain and the antigen-binding functional region linked thereto, tend to form a heterodimer when co-expressed in a cell. When the first Fc chain and the second Fc chain, or the first Fc chain and the second Fc chain and the antigen-binding functional region linked thereto, are separately expressed in two host cells, the first Fc chain or the first Fc chain and the antigen-binding functional region linked thereto do not tend to form a homodimer, and the second Fc chain or the second Fc chain and the antigen-binding functional region linked thereto do not tend to form a homodimer. In the present invention, the first Fc chain and the second Fc chain, or the first Fc chain and the second Fc chain and the antigen-binding functional region linked thereto, are expressed separately in two host cells in the presence of a reducing agent, and the proportion of homodimers is less than 50%, i.e., the proportion of monomers (the Fc chains or the Fc chains and the antigen-binding functional region linked thereto) is more than 50%.
[0052] Immunoglobulins have a symmetrical structure of four polypeptide chains, including two identical heavy chains that are longer and have a higher relative molecular weight, containing 450-550 amino acid residues and a relative molecular weight of 55,000 Da to 70,000 Da, and two identical light chains (L chains) that are shorter and have a lower relative molecular weight, containing about 210 amino acid residues and a relative molecular weight of about 24,000 Da. A sequence of about 110 amino acids near the N-terminus is highly variable in different immunoglobulin heavy and light chains and is known as the variable region (V region). The remaining amino acid sequence near the C-terminus is relatively stable and is known as the constant region (C region). In the heavy chain, the variable region occupies about 1 / 4 of the length of the heavy chain, while the constant region occupies about 3 / 4 of the length of the heavy chain. Regarding the five known Ig isotypes, namely IgG(γ), IgA(α), IgD(δ), IgM(μ) and IgE(ε), there are three constant regions in the H chain of the first three Ig isotypes, namely CH1, CH2 and CH3. In the H chain of the latter two isotypes (IgM and IgE), there is one VH region and four constant regions, namely CH1-CH4. The constant regions are the framework of the immunoglobulin molecule as well as one of the regions that activate the immune response.
[0053] In the present invention, the portion of the constant region includes at least the interaction region of the first Fc chain and the second Fc chain. For IgG, the region is at least some amino acids in the CH3 region, including GLN347, TYR349, THR350, LEU351, SER354, ARG355, ASP356, GLU357, LYS360, SER364, THR366, LEU368, LYS370, ASN390, LYS392, THR394, PR0395, VAL397, ASP399, SER400, PHE405, TYR407, LYS409, and LYS439.
[0054] The linkage of the first Fc chain and the second Fc chain to "one antigen-binding functional region" via a covalent bond or a linker means that the first Fc chain and the second Fc chain are linked to an antigen-binding fragment of an antibody, or a single-chain antibody capable of recognizing an antigen, or another allosteric antibody fragment capable of recognizing an antigen, or a receptor capable of recognizing a ligand, or a ligand capable of recognizing a receptor, via a covalent bond or a linker. The covalent bond is a type of chemical bond in which two or more atoms share their outer electrons, ideally reaching a saturated state, thereby forming a relatively stable chemical structure called a covalent bond. In other words, the covalent bond is an interaction formed between atoms by sharing electron pairs. Atoms of the same element and different elements can both be bonded via the covalent bond. The covalent bond between the first Fc chain and the second Fc chain of the present invention includes, but is not limited to, an amide bond formed by a dehydration reaction between an amino group of one amino acid molecule and a carboxyl group of another amino acid molecule, or an amide bond or an imine bond formed from an aldehyde group of ethylene glycol, or polyethylene glycol, or other compounds or polymers thereof and an amino group of one amino acid molecule. The linker is a compound or a polymeric compound segment that can link an amino acid sequence or two polypeptide chains via a covalent bond. The amino acid sequence segment includes, but is not limited to, a small peptide segment such as GGGSGGGGSGGGGGS. The first Fc chain or the second Fc chain and a single chain antibody capable of recognizing an antigen or other allosteric antibody fragment capable of recognizing an antigen can be linked via an amide bond.
[0055] The context of "the first Fc chain and the second Fc chain tend to form heterodimers rather than homodimers of each other" refers to the fact that, with respect to the first Fc chain and the second Fc chain, due to the repulsive forces existing between the same chains and the attractive forces existing between different chains, the first Fc chain and the second Fc chain, or the first Fc chain and the second Fc chain and the antigen-binding functional region linked thereto, tend to form heterodimers when co-expressed in a cell. When the first Fc chain and the second Fc chain, or the first Fc chain and the second Fc chain and the antigen-binding functional region linked thereto, are separately expressed in two host cells, the first Fc chain or the first Fc chain and the antigen-binding functional region linked thereto do not tend to form homodimers, and the second Fc chain, or the second Fc chain and the antigen-binding functional region linked thereto do not tend to form homodimers.
[0056] The Kabat index numbering system refers to the method used by Kabat to assign a number to each amino acid in an antibody sequence, which has become standard practice in the art. The Kabat numbering scheme can be extended beyond his work to other antibodies. Based on conserved amino acids, the target antibody is aligned with one of the consensus sequences identified by Kabat.
[0057] "Fc domain" refers to the fragment crystallizable region (Fc) corresponding to the CH2 and CH3 domains of Ig, the portion of Ig that interacts with effector molecules or cells.
[0058] IgG, short for immunoglobulin G (IgG), is the major antibody component in serum. Human IgG is classified into four subclasses, IgG1, IgG2, IgG3, and IgG4, based on antigenic differences in the r chain of the IgG molecule.
[0059] A "half antibody" molecule refers to a structure formed by one heavy chain and one light chain of an antibody, which may or may not be linked via a covalent bond. It is a monovalent antibody structure that recognizes an antigen.
[0060] "Fab fragment", i.e., a fragment of antigen binding (Fab), is a molecular recognition sequence corresponding to the two arms of an antibody molecule, consisting of an intact light chain and the VH and CHI domains of the heavy chain. "scFv" is a molecular recognition sequence, an engineered antibody fragment obtained by genetic engineering of the light chain variable region and the heavy chain variable region of an antibody. The "extracellular region" of a membrane receptor is a molecular recognition sequence. The membrane receptor generally includes an extracellular region located outside the cell that recognizes and binds to the corresponding antigen or ligand, a transmembrane region that anchors on the receptor on the cell surface, and an intracellular region inside the cell that has intracellular kinase activity or can transmit a signaling pathway. The "ligand" of a cell membrane receptor refers to a protein, small peptide, or compound that can be recognized and bound by the extracellular region of the membrane receptor. Cytokines are low molecular weight soluble proteins that are produced by various types of cells induced by immunogens, mitogens, or other stimuli and have various functions such as innate and adaptive immunity, hematopoiesis, cell growth, regulation of adult pluripotent stem cells (APSCs), and repair of damaged tissue. Cytokines are classified as interleukins, interferons, tumor necrosis factor superfamily, colony stimulating factors, chemokines, growth factors, etc. "Protein expression tag" refers to a segment of amino acid sequence, either a small peptide or a length of amino acids, that is added to the N- or C-terminus of a target protein. The addition of a tag can be advantageous for correct folding of the protein, isolation and purification of the protein, and reduction of intracellular degradation of the protein. Commonly used tags include, but are not limited to, HA, SUMO, His, GST, GFP, and Flag.
[0061] There is no limitation on the antibodies applicable to the heterodimeric bispecific antibodies of the present invention. Preferably, any antibody known in the art for the treatment and / or prevention of disease can be used in the present invention.
[0062] The heterodimeric bispecific antibody of the present invention may have one or more substitutions, deletions, additions, and / or insertions. For example, some amino acids can be substituted with other amino acids in the protein structure without significant loss of potential in binding to other polypeptides (e.g., antigens) or cells. Since the biological functional activity of a protein is determined by the binding ability and properties of the protein, the protein sequence can be subjected to some amino acid sequence substitutions without significant loss of its biological effector activity.
[0063] Often, a polypeptide variant contains one or more conservative substitutions. "Conservative substitution" refers to the substitution of an amino acid with another amino acid having similar properties such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophilic properties of the polypeptide to remain substantially unchanged.
[0064] Amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, such as their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions taking into account various properties are well known to those of skill in the art and include arginine and lysine, glutamic acid and aspartic acid, serine and threonine, glutamine and asparagine, as well as valine, leucine, and isoleucine.
[0065] The term "identity" as used in the present invention has the meaning generally known in the art and refers to the percentage of the same residues between a polynucleotide or polypeptide sequence variant and a non-variant sequence when the sequences are aligned and gaps are introduced (if necessary to achieve the maximum homology percentage). The rules and categories for determining the identity between different sequences are also known to those skilled in the art. In the present invention, when the definition of identity is satisfied, it is also required that the resulting variant sequence has the biological activity possessed by the parent sequence. Methods and means for screening variant sequences with activity are well known to those skilled in the art. From the teachings disclosed herein, those skilled in the art will easily achieve such variant sequences. In specific embodiments, the polynucleotide and polypeptide variants have at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%, or at least about 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% polynucleotide or polypeptide identity to the polynucleotides or polypeptides described herein. Due to the redundancy of the genetic code, there are variants that encode the same amino acid sequences as these sequences.
[0066] In another embodiment of the present invention, a polynucleotide composition is provided that can hybridize with the polynucleotide sequence provided by the present invention, or its fragment, or its complementary sequence, under moderate to high stringency conditions. Hybridization techniques are well known in the field of molecular biology. For illustrative purposes, suitable moderately stringent conditions for testing the hybridization of the polynucleotide of the present invention with other polynucleotides include pre-washing with a solution of 5xSSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridizing overnight under 5xSSC conditions at 50°C to 60°C, and washing twice for 20 minutes with 2x, 0.5x, and 0.2xSSC containing 0.1% SDS at 65°C. Those skilled in the art will appreciate that the stringency of hybridization can be easily manipulated, for example, by changing the salt content of the hybridization solution and / or the hybridization temperature. For example, in another embodiment, suitable highly stringent hybridization conditions include conditions other than increasing the hybridization temperature, for example to 60-65°C or 65-70°C.
[0067] The host cell of the present invention can be any cell used for heterologous gene expression, including, but not limited to, E. coli, yeast, insect cells, plant cells, and mammalian cells.
[0068] The vectors of the present invention include vectors that can replicate in any type of cell or organism, including, but not limited to, plasmids, bacteriophages, cosmids, and minichromosomes. In some embodiments, the vectors that contain the polynucleotides of the present invention are suitable for propagation or replication of the polynucleotides, or suitable for expression of the polypeptides of the present invention. Such vectors are known in the art and commercially available.
[0069] "Vector" includes shuttle vectors and expression vectors. Generally, a plasmid construct also includes an origin of replication (e.g., CoEl replication origin) and a selectable marker (e.g., ampicillin or tetracycline resistance) that is used for plasmid replication and selection in bacteria, respectively. "Expression vector" refers to a vector that includes the necessary control sequences or regulatory elements to express the antibody of the present invention, including antibody fragments, in bacteria or eukaryotic cells.
[0070] The vector of the present invention can be any vector used for heterologous gene expression, including but not limited to a plasmid vector, which contains at least an origin of replication, a promoter, a gene of interest, multiple cloning sites and a selection marker gene.Preferably, the vector of the present invention includes a plasmid vector obtained by modification based on pcDNA, such as but not limited to the X0GC vector.
[0071] The subject of the present invention includes poultry, reptiles, mammals, etc. Preferably, said mammals include rodents and primates. Preferably, said primates include humans.
[0072] The range of diseases relevant to the present invention includes, but is not limited to, tumors, preferably including leukemia, lymphoma, myeloma, brain tumor, head and neck squamous cell carcinoma, non-small cell lung cancer, nasopharyngeal cancer, esophageal cancer, gastric cancer, pancreatic cancer, gallbladder cancer, liver cancer, colorectal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, bladder cancer, renal cell carcinoma, and melanoma.
[0073] Pharmaceutically acceptable carrier refers to pharmaceutical carriers commonly used in the field of pharmaceutical preparations, such as diluents, excipients, water, etc., fillers such as starch, sucrose, lactose, microcrystalline cellulose, binders such as cellulose derivatives, alginates, gelatin and polyvinylpyrrolidone, wetting agents such as glycerin, disintegrants such as sodium carboxymethyl starch, hydroxypropylcellulose, crosslinked carboxymethylcellulose, agar, calcium carbonate, sodium bicarbonate, absorption enhancers such as quaternary ammonium compounds, surfactants such as hexadecanol, sodium lauryl sulfate, adsorption carriers such as kaolinite, bentonite, lubricants such as talc, calcium stearate and magnesium stearate, micronized silica gel and polyethylene glycol.In addition, other adjuvants such as flavorings and sweeteners may be added to the composition.
[0074] The present invention will be further described herein with reference to the following non-limiting examples. It is well known to those skilled in the art that various modifications can be made to the present invention without departing from the spirit of the present invention. Such modifications are also included within the scope of the present invention. EXAMPLES
[0075] The following experimental methods are all conventional methods unless otherwise stated. The experimental materials employed are readily available from commercial companies unless otherwise stated. The antibodies used in the following examples of the present invention are all commercially available standard antibodies.
[0076] Example 1. Vector construction of heterodimeric antibody molecules X0GC expression vectors containing the heavy and light chains of anti-PD-L1 antibodies were constructed, respectively, and the sequences of the antibody variable regions were obtained from https: / / www.drugbank.ca / drugs / DB11595. The heavy chain constant region was derived from human IgG1. The nucleotide sequence of the light chain variable region is shown as SEQ ID NO:1, its amino acid sequence is shown as SEQ ID NO:2, the nucleotide sequence of the light chain constant region is shown as SEQ ID NO:3, its amino acid sequence is shown as SEQ ID NO:4, the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO:5, its amino acid sequence is shown as SEQ ID NO:6, the nucleotide sequence of the heavy chain constant region is shown as SEQ ID NO:7, its amino acid sequence is shown as SEQ ID NO:8. The light chain variable region and the light chain constant region, the heavy chain variable region and the heavy chain constant region were amplified by PCR, respectively. Phusion High-Fidelity DNA polymerase (F-530L, NEB, Inc.) was used in all PCR reactions in this application. PCR primers were conventionally designed according to the principle of complementary base pairing and the requirement of enzyme digestion sites. All reaction systems were 8.9 μl H2O, 4 μL 5× Phusion high fidelity DNA polymerase buffer, 4 μL 1 mM dNTP, 1 μl upstream primer, 1 μl downstream primer, 0.1 μl Phusion high fidelity DNA polymerase, and 1 μl template. The PCR products of the variable and constant regions were subjected to 1.5% agarose gel electrophoresis, and the corresponding fragments were recovered using a DNA recovery kit (Promega, A9282, the same below). Further PCR was performed using the upstream primer of the variable region and the downstream primer of the constant region with the recovered variable and constant region fragments as templates. The corresponding fragments were then recovered to obtain the full-length fragments of the light or heavy chain. The X0GC vector and full-length fragment were digested with EcoRI (NEB, Cat. No. R3101L) and HindIII (NEB, Cat. No. R3104L).The enzyme digestion reaction system was 2 μL of 10× buffer 3, 0.5 μl each of EcoRI and HindIII, 3 μL of full-length fragment recovered from the gel, and 14.5 μL of H2O. The enzyme digestion reaction system was reacted at 37° C. for 3 hours. The enzyme digestion products were ligated with T4 DNA ligase (NEB, catalog number M0202V) (same below). The reaction system was 2 μl of 10× ligase buffer, 0.5 μl of ligase, 3 μl of full-length fragment recovered from the gel, 3 μl of X0GC vector recovered from the gel, and 11.5 μl of H2O. The ligation was carried out at room temperature for 12 hours. The ligated products were transformed into E. coli DH5α competent cells (Tiangen, CB104, the same below), to obtain X0GC expression vectors of antibody heavy chain and light chain for expressing antibody heavy chain and light chain in eukaryotic cells, respectively.
[0077] The X0GC expression vectors of the heavy and light chains of anti-PD-1(Pem) antibody were constructed respectively, and the sequences of the antibody variable regions were obtained from http: / / www.imgt.org / 3Dstructure-DB / cgi / details.cgi?pdbcode=9798, the nucleotide sequence of the light chain variable region is shown as SEQ ID NO:9, its amino acid sequence is shown as SEQ ID NO:10, the nucleotide sequence of the light chain constant region is shown as SEQ ID NO:3, its amino acid sequence is shown as SEQ ID NO:4, the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO:11, its amino acid sequence is shown as SEQ ID NO:12, the nucleotide sequence of the heavy chain constant region is shown as SEQ ID NO:13, its amino acid sequence is shown as SEQ ID NO:14. The X0GC expression vectors of the antibody heavy and light chains were obtained for expressing the antibody heavy and light chains, respectively, in eukaryotic cells.
[0078] The X0GC expression vectors of the heavy and light chains of anti-PD-1 antibody (BJHM) were also constructed in the present invention. The nucleotide sequence of the light chain variable region is shown as SEQ ID NO: 15, its amino acid sequence is shown as SEQ ID NO: 16, the nucleotide sequence of the light chain constant region is shown as SEQ ID NO: 3, its amino acid sequence is shown as SEQ ID NO: 4, the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO: 17, its amino acid sequence is shown as SEQ ID NO: 18, the nucleotide sequence of the heavy chain constant region is shown as SEQ ID NO: 13, its amino acid sequence is shown as SEQ ID NO: 14. The X0GC expression vectors of the antibody heavy chain and light chain were obtained for expressing the antibody heavy chain and light chain, respectively, in eukaryotic cells.
[0079] Example 2. Expression of heterodimeric antibody molecules The antibody heavy and light chain expression vectors were co-transfected into the 293F cell line (FreeStyle™ 293-F cells, Catalog No. R79007, Invitrogen). Cells were seeded the day before transfection. On the day of transfection, the cells were harvested by centrifugation and then seeded at 200×10 in fresh FreeStyle™ 293 Expression Medium (Cat. No. 12338001, Gibco). 5 The cells were resuspended at a cell density of 10000 cells / mL. Plasmids were added according to the transfection volume to a final concentration of 36.67ug / mL and mixed gently. Linear PEI (Polyethyleneimine, Linear, MW25000, Cat. No. 43896, Alfa Aesar) was then added to a final concentration of 55ug / mL and mixed gently. The mixture was then placed in a cell incubator and incubated for 1 hour at 37°C at 120 rpm in a shaker. Fresh medium was then added in a volume 19 times the transfection volume. Incubation continued at 37°C at 120 rpm in a shaker. The supernatants of the 5-6 day transfected cell cultures were collected by centrifugation.
[0080] The expression level was determined by ELISA. The precipitate was removed by filtration through a 0.2 μm filter membrane before purification by applying a chromatography column. This step was performed at 4° C.
[0081] Example 3. Purification of heterodimeric antibody molecule expression products Purification was performed using an AKTA Explorer100 Protein Purification System (GE Healthcare) and a rProtein A Sepharose Fast Flow affinity chromatography column (16mmLD, 22ml, GE Healthcare) at 4℃. First, the chromatography column was equilibrated with mobile phase A (20mM sodium phosphate buffer, 150mM sodium chloride, PH7.4). After the baseline was stabilized, the cell supernatant treated as described above was loaded at a flow rate of 5ml / min. After the loading process, mobile phase A was used for equilibration. Then, 5 column volumes of mobile phase B1 (mobile phase A+0.5M arginine) were used to wash the column, and 5 column volumes of mobile phase B2 (100mM citric acid, PH3.0) were used to elute and collect the elution peak, i.e., the peak of the protein of interest. The flow rate was 5ml / min for all elution steps. The chromatogram of the elution peak of the anti-PD-L1 expression product is shown in Figure 1. The elution peak of the anti-PD-1 expression product is similar to this (results not included). The indicated elution peak (shown in grey) was collected and the pH was adjusted to pH 5.0 by dropwise addition of 1 M sodium acetate solution.
[0082] The purified products were analyzed by SDS-PAGE, and the results are shown in FIG.
[0083] Example 4. Preparation and purification of anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules The structure of the anti-PD-L1 / anti-PD-1 heterodimer antibody molecule is shown in Figure 3.
[0084] The half antibody molecules of the antibodies obtained by the method of rProtein A Sepharose Fast Flow (16mmI.D., 22ml, GE Healthcare) were subjected to in vitro reconstitution to obtain heterodimers. The protein solution purified and collected as described above was first concentrated by ultrafiltration through an ultrafiltration concentration tube (nominal cut-off molecular weight of 10kDa), and then the solution was replaced with phosphate buffered saline (PBS) (pH=7.4). The obtained molecular solutions of the half antibody molecules of anti-PD-L1 and anti-PD-1 antibodies were adjusted to 1mg / ml by adding PBS, respectively. 1M DTT was added at 1 / 200 times the final solution so that the final concentration of DTT was 5mM, respectively. Reduction was carried out at 4℃ (3-8 hours) to cleave the disulfide bonds. The disulfide bonds in the hinge region of the homodimeric antibody molecules present in small amounts in the anti-PD-1 half antibody molecules were also cleaved, thereby forming half antibody molecules containing one heavy chain and one light chain, as shown in Figure 4. The reduced samples were analyzed by SEC-HPLC. The percentage of the half antibody molecules was more than 90%.
[0085] Then, the reduced anti-PD-L1 and anti-PD-1 half antibody molecules were mixed in an equal molar ratio and subjected to a reconstitution reaction at 4℃ for 24 hours. During the reconstitution, a heterodimeric bispecific antibody containing both the anti-PD-L1 and the anti-PD-1 half antibody molecules was formed from the anti-PD-L1 and the anti-PD-1 half antibody molecules via non-covalent interactions between CH2 / CH3. The protein solution was then concentrated by ultrafiltration through an ultrafiltration concentration tube (nominal molecular weight cut-off of 10 kDa). The reduction was stopped by replacing the solution with phosphate buffered saline (PBS) (pH-7.4). Oxidation was carried out in air or using an oxidizing agent to reorganize the disulfide bonds of the heterodimeric bispecific antibody. The oxidation conditions were as follows: 100 mM L-dehydroascorbic acid was added as an oxidizing agent, the final concentration of the protein was 1 mg / ml, and the final concentration of the oxidizing agent was 1 mM, and the oxidation reaction was carried out at 4℃ for 24 hours. The sample obtained by the oxidation reaction was subjected to SDS-PAGE analysis, and the results are shown in FIG.
[0086] The heterodimer molecules obtained by reduction-oxidation of the anti-PD-L1 and the anti-PD-1 half antibody molecules were concentrated by ultrafiltration through an ultrafiltration concentration tube (nominal cut-off molecular weight of 10 kDa). The solution was replaced with 10 mM sodium phosphate buffer (pH=5.8). Purification was carried out at 4°C using an AKTA Explorer 100 Protein Purification System (GE Healthcare) and an ion chromatography column Source 15S (16 mm I.D., 17 ml, GE Healthcare). First, the chromatography column was equilibrated with mobile phase A (10 mM sodium phosphate buffer, pH 7.0). After the baseline was stabilized, the protein solution treated as above was loaded at a flow rate of 3 ml / min. After the loading process, mobile phase A was used for equilibration. The column was then eluted with a gradient of A (10 mM sodium phosphate, pH 5.8) to B (10 mM sodium phosphate, pH 5.8) (0% B-100% B, 170 min, flow rate 2 ml / min) over 20 column volumes. The indicated main elution peak was collected (shown in Figure 6) and the collected protein solution was concentrated by ultrafiltration through an ultrafiltration concentration tube (nominal molecular weight cut-off of 10 kDa). The solution was replaced with phosphate buffered saline (PBS, pH=7.4), sterilized by filtration and stored at 4°C. The purified product was analyzed by SDS-PAGE method. The results are shown in Figure 7. Purity analysis by SEC-HPLC showed a purity of 96.44% with the results shown in Figure 8.
[0087] Example 5. In vitro target binding activity of anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules The binding ability of PD-L1 / PD-1 heterodimer antibodies to single antigens was measured by enzyme-linked immunosorbent assay (ELISA).
[0088] The detailed process of the assay is as follows: Recombinant human PD-L1 (Beijing Sino Biological Inc., Catalog No. 10377-H08H) or human PD-1 (Beijing Sino Biological Inc., Catalog No. 10377-H08H) was coated onto a 96-well high-binding ELISA plate at a coating concentration of 1 μg / mL with a coating volume of 100 μL per well using carbonate buffer at pH 9.6. Coating was performed overnight at 4°C. The plate was washed five times with PBST. The plate was then blocked with 300 μL / well of PBST containing 1% BSA, incubated at 25°C for 1 hour, and then washed five times with PBST. Samples and controls of heterodimeric antibodies, serially diluted in PBST containing 1% BSA, were added at 100 μL / well and incubated at 25°C for 1 hour. The plate was washed five times with PBST. Horseradish peroxidase-labeled anti-human IgG antibody (Chemicon, Cat. No. AP309P), diluted 1:2000 in PBST containing 1% BSA, was then added at 100 μL / well and incubated for 1 hour at 25° C. The plate was washed 5 times with PBST. The color substrate TMB was added at 100 μL / well and allowed to develop for 10 minutes at room temperature. Color development was stopped by adding 100 μL / well of 1M H2SO4. The absorbance at 450 nm was read on a microplate reader.
[0089] According to the results shown in Figure 9, anti-PD-L1 / anti-PD-1 pem and anti-PD-L1 / anti-PD-1 BJHM Both of these antibodies had high affinity for PD-L1 and PD-1, and the antigen affinity activity of the bivalent monoclonal antibody was fully retained. BJHM is anti-PD-L1 / anti-PD-1 pem It has a higher affinity for PD-1 than
[0090] Example 6. Activity of anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules in inducing cell binding by simultaneously binding to dual targets The activity of PD-L1 / PD-1 heterodimer antibodies to induce cell binding by simultaneously binding to dual targets was measured on HCC827 cells (GenScript, catalog no. M00529) expressing PD-L1 and CHO / PD-1 cells with high PD-1 expression by fluorescence-activated cell sorting (FACS).
[0091] CHO / PD-1 cells were stained according to the instructions of the PKH26 kit (Sigma, Cat. No. SLBH4568V). Briefly, CHO / PD-1 cells were harvested, washed once with serum-free medium, and stained at 2 × 10 7 PKH26 dye was diluted to 4 μM in Diluent C and mixed with the cell suspension in a 1:1 ratio. 7 The mixed suspension with a cell density of 1000 / ml and a PKH26 concentration of 2 μM was incubated at room temperature for 1 min, then incubated with an equal volume of FBS for 1 min to stop the staining. The suspension was centrifuged at 400 g for 10 min, washed twice with complete medium, and resuspended in complete medium for further use. HCC827 cells were stained according to the instructions of the CFSE kit (Life technologies, Catalog No. C34554). Briefly, CFSE was diluted with PBS to a working concentration of 0.5 PM and pre-warmed at 37°C. HCC827 cells were collected by centrifugation at 1000 rpm for 5 min, then suspended in pre-warmed CFSE working solution, and incubated at 37°C for 15 min. Cells were collected by centrifugation at 1000 rpm for 5 min, resuspended in complete medium, and incubated for 30 min. The cells were then washed once with the complete medium, and then resuspended in the complete medium for further use.
[0092] Stained cells were collected by centrifugation and washed once with cold PBS containing 2% FBS. The cells were diluted to 5 × 106 The HCC827 and CHO / PD-1 cells were mixed in a 1:1 ratio. 100 μL of the cell mixture was collected into each flow tube (i.e., 2.5 × 10 5 HCC827 and 2.5 x 10 5 CHO / PD-1), then 100 μL of heterodimeric antibody sample, control, or isotype control (human immunoglobulin, Jiangxi Boya Biopharmaceutica1 Co,, Ltd., National Drug Approval No. S19993012) diluted in cold PBS containing 2% FBS was added. The flow tubes were incubated on ice for 30 minutes, washed twice with PBS containing 2% FBS, and then resuspended in 500 μL of cold PBS. The cell suspensions were detected and analyzed by flow cytometry.
[0093] The results are shown in Table 1 and Figure 10. By simultaneously binding to HCC827 cells expressing PD-L1 and CHO / PD-1 cells with high PD-1 expression using heterodimeric antibodies, the PD-L1 / PD-1 heterodimeric antibodies can induce tight binding between HCC827 and CHO / PD-1 cells, which is the basis for mediating tumor cell killing by T cells.
[0094] [Table 1]
[0095] Example 7. T cell regulatory activity of anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules The modulatory activity of PD-L1 / PD-1 heterodimer antibodies on T cell immune responses was determined by mixed lymphocyte reaction (MLR).
[0096] Obtaining human dendritic cells (DCs): Human PBMC cells (Lonza, Cat. No. CC-2702) were resurrected and collected. The human PBMC cells were cultured at 5×10 6The cells were resuspended at a cell density of 100 ng / ml, inoculated into a cell culture flask, and incubated at 37°C in a CO2 incubator for 90 minutes. After discarding the culture supernatant and suspending the cells, the adherent cells were cultured in complete medium (RPMI1640 with 10% FBS) supplemented with 100 ng / ml GM-CSF (Beijing Sino Biological Inc., Catalog No. 10015-HNAH) and 100 ng / ml IL-4 (Beijing Sino Biological Inc., Catalog No. 11846-HNAE). After 3 days of incubation, the medium was replaced and the cells were incubated for another 3 days. Then, the culture medium was replaced with the complete medium (RPMI1640 with 10% FBS) containing 100 ng / ml GM-CSF, 100 ng / ml IL-4, and 20 ng / ml TNF-α, and the cells were incubated for 1 day to obtain DC cells.
[0097] Obtaining human T cells: Human PBMC cells were resurrected and collected, and then PBMCs for deriving PBMCs and DC cells were derived from different individuals. Human T cells were separated according to the instructions of the Pan T Cell Separation Kit (Miltenyi Biotech, Cat. No. 5150414820). Briefly, the PBMCs were washed once with PBS and diluted with 10 PBS per 40 μL of separation buffer (PBS containing 2 mM EDTA, 0.5% BSA, pH=7.2). 7 The cells were resuspended in 10 mL of 10% CO. 7 (Calculated per cell). 10 μL of Pan T cell Biotin Antibody Cocktail was added and incubated at 4°C for 5 min. Then, 30 μL of separation buffer and 20 μL of Pan T cell MicroBead Cocktail were added and incubated at 4°C for 10 min. T cells were obtained through a MACS separation column.
[0098] The collected human DC cells and human T cells were resuspended in complete medium (RPMI1640 containing 10% FBS) and plated on a 96-well plate at 1 × 104 / well and 1 x 10 5 1000 x 1000 cells / well, respectively, and cultured in the mixture. The PD-L1 / PD-1 heterodimer antibody samples and controls serially diluted in complete medium were added. The culture plate was placed in a CO2 incubator for incubation at 37°C for 5 days. After incubation was completed, the supernatants in the wells were harvested and the cytokines IL-2 (Ray Biotech, Catalog No. ELH-IL2) and IFN-γ (Ray Biotech, Catalog No. ELH-IFNg) were detected according to the kit manual.
[0099] As shown in Figure 11, human T cells stimulated by allogeneic DC cells can activate and secrete IL-2 and IFN-γ. The addition of PD-L1 antibody or PD-1 antibody can enhance the activation of T cells and promote the secretion of cytokines. PD-L1 / PD-1 heterodimer antibody has stronger T cell regulating activity than monoclonal antibody, and more significantly promotes the secretion of cytokines IL-2 and IFN-γ.
[0100] Example 8. In vitro killing activity of anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules against tumor cells HCC827 tumor cells were harvested. HCC827 cells were cultured in complete medium (RPMI1640 containing 10% FBS) at 5 × 10 4 Resuspend cells at a cell density of 100 µL / mL and plate 100 µL per well in a 96-well plate (5 × 10 cells in each well). 3 Plates were incubated at 37°C for 3-4 hours in a CO2 incubator. Human PBMC cells (Lonza, Cat. No. CC-2702) were resuspended and collected. The PBMCs were seeded at 2 x 10 6 Resuspend cells at a cell density of 10 x 10 / mL and place 50 µL / well (1 x 10 per well) in a 96-well plate at a 20:1 effector to target cell ratio. 5The plate was placed in a CO2 incubator for incubation at 37°C for 3 days. At the end of the incubation, the culture supernatant and suspended PBMC cells were discarded. HCC827 cells were washed twice with PBS to remove residual PBMC. Finally, 100 μL of the complete medium and 20 μL of MTS chromogen (Promega, Cat. No. G358B) were added and incubated for 2-3 hours. The absorbance at 490 nm was detected by a microplate reader.
[0101] As shown in Figure 12, Trop-2 / CD3 heterodimer antibody initiated cell killing by PBMCs on HCC827 tumor cells, and PD-L1 antibody or PD-1 antibody could enhance the killing effect of PBMCs on tumor cells in a concentration-dependent manner, while PD-L1 / PD-1 heterodimer antibody had stronger killing activity against tumor cells than monoclonal antibody and monoclonal antibody combination.
[0102] Example 9. Antitumor effects of anti-PD-L1 / anti-PD-1 heterodimeric antibody molecules in xenograft tumor models Female NPG (NOD-Prkdc) mice aged 6 to 8 weeks were purchased from Beijing Vitalstar Biotechnology Co. Ltd. scid Il2rg null ) mice were used as experimental subjects. After 1 week of adaptation to the environment, 5 × 10 6 HCC827 human lung cancer cells were inoculated subcutaneously into the right dorsal region of each mouse. 3Once the tumors had grown to 100 mm Hg, the mice were grouped according to the tumor volume, with 6 tumor-bearing mice per group. Each animal was administered vehicle (PBS), 70 nmol / kg PD-L1 monoclonal antibody, 70 nmol / kg PD-1 monoclonal antibody, 70 nmol / kg PD-L1 monoclonal antibody + 70 nmol / kg pharmaceutical composition with PD-L1 monoclonal antibody, or 70 nmol / kg anti-PD-L1 / anti-PD-1 heterodimer by intraperitoneal injection twice weekly for 2 weeks. Starting from the day of administration, the tumor volume was measured 3 times a week. The long diameter a and short diameter b were measured, and the tumor volume was calculated according to the formula: tumor volume (mm 3 )=(a×b 2 ) / 2.
[0103] The results are shown in Figure 13. Both PD-L1 mAb and PD-1 mAb showed antitumor effects, but the PD-L1 / PD-1 heterodimer antibody showed stronger antitumor effects than the monoclonal antibody and the combination of monoclonal antibodies. Moreover, good tumor control was observed even after drug discontinuation.
Claims
1. a heterodimeric bispecific antibody comprising a first antigen-binding functional region capable of specifically binding to PD-L1 and a second antigen-binding functional region capable of specifically binding to PD-1, said bispecific antibody comprising a first Fc chain and a second Fc chain linked by one or more interchain disulfide bonds, said first Fc chain and said second Fc chain being linked to a PD-L1 antigen-binding functional region and a PD-1 antigen-binding functional region, respectively, by a covalent bond or a linker, or said first Fc chain and said second Fc chain being linked to said PD-1 antigen-binding functional region and said PD-L1 antigen-binding functional region, respectively, by a covalent bond or a linker, and said first Fc chain and said second Fc chain comprising five amino acid substitutions; wherein the amino acid substitutions in the first Fc chain are T366L and D399R, and the amino acid substitutions in the second Fc chain are L351E, Y407L, and K409V; the first Fc chain and the second Fc chain containing the amino acid substitution tend to form heterodimers with each other rather than homodimers with each other; and The PD-L1 antigen-binding functional region comprises the amino acid sequences shown in SEQ ID NOs: 2 and 6, and the PD-1 antigen-binding functional region comprises the amino acid sequences shown in SEQ ID NOs: 16 and 18; A heterodimeric bispecific antibody, wherein the amino acid positions are numbered according to the Kabat EU index numbering system.
2. The heterodimeric bispecific antibody of claim 1 , wherein the Fc chain is derived from IgG.
3. The heterodimeric bispecific antibody of claim 1 or 2, wherein the PD-L1 antigen binding functional region and the PD-1 antigen binding functional region are Fab fragments or scFv fragments.
4. The heterodimeric bispecific antibody according to any one of claims 1 to 3, wherein the PD-L1 antigen binding functional region and the PD-1 antigen binding functional region are both Fab fragments.
5. The heterodimeric bispecific antibody according to any one of claims 1 to 3, wherein one of the PD-L1 antigen binding functional region and the PD-1 antigen binding functional region is a Fab fragment, and the other is an scFv.
6. The first Fc chain and the PD-L1 antigen binding functional region linked thereto, and the second Fc chain and the PD-1 antigen binding functional region linked thereto, or the first Fc chain and the PD-1 antigen binding functional region linked thereto, and the second Fc chain and the PD-L1 antigen binding functional region linked thereto, when present alone in the presence of a reducing agent, form a homodimer at a ratio of less than 50% by weight. The heterodimeric bispecific antibody according to any one of claims 1 to 5.
7. The heterodimeric bispecific antibody according to any one of claims 1 to 6, comprising a heavy chain constant region comprising the amino acid sequences shown in SEQ ID NOs: 8 and 14, respectively.
8. A composition comprising the heterodimeric bispecific antibody of any one of claims 1 to 7 and a pharma- ceutically acceptable carrier.
9. Use of a heterodimeric bispecific antibody according to any one of claims 1 to 7 and / or a composition according to claim 8 in the manufacture of a medicament for preventing and / or treating a disease in a subject.
10. The use according to claim 9, wherein the subject is a mammal.
11. 10. The use according to claim 9, wherein the disease is a tumor selected from the group consisting of leukemia, lymphoma, myeloma, brain tumor, squamous cell carcinoma of the head and neck, non-small cell lung cancer, nasopharyngeal cancer, esophageal cancer, gastric cancer, pancreatic cancer, gallbladder cancer, liver cancer, colorectal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, bladder cancer, renal cell carcinoma, and melanoma.
12. A heterodimeric bispecific antibody according to any one of claims 1 to 7 and / or a composition according to claim 8 for use as a medicament for the prevention and / or treatment of a disease in a subject.
13. The heterodimeric bispecific antibody or composition of claim 12, wherein the subject is a mammal.
14. 13. The heterodimeric bispecific antibody or composition of claim 12, wherein the disease is a tumor selected from the group consisting of leukemia, lymphoma, myeloma, brain tumor, head and neck squamous cell carcinoma, non-small cell lung cancer, nasopharyngeal carcinoma, esophageal cancer, gastric cancer, pancreatic cancer, gallbladder cancer, liver cancer, colorectal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, bladder cancer, renal cell carcinoma, and melanoma.
Citation Information
Patent Citations
Design of stable heterodimer antibodies with mutations in the Fc domain
JP2014504265A
Antibodies and other molecules that bind to B7-H1 and PD-1
JP2014523401A
Production of heterodimeric proteins
JP2014530891A
Design of stable heterodimer antibodies with mutations in the Fc domain
JP2014533243A
Method and means for producing Ig-like molecules
JP2015514417A
